PDZK1 regulates multiple processes through its scaffolding activity:
Ion Transport: Modulates proximal tubular Na+-dependent phosphate cotransport and CFTR chloride channel activity .
Cholesterol Metabolism: Connects SCARB1 (scavenger receptor) with intracellular cholesterol transport machinery .
Drug Resistance: Interacts with ABCC2 (multidrug resistance protein 2) and PDZK1IP1 to influence cellular drug efflux .
PDZK1 forms complexes with:
Additional interactors include AKAP10, CLCN3, and SLK .
Antibody Validation: The recombinant fragment (aa 1–96) serves as a control for antibody specificity (e.g., Thermo Fisher PA5-52261) .
Blocking Protocol: Recommended 100x molar excess of PDZK1 fragment pre-incubated with antibodies for 30 minutes .
Osteoarthritis: PDZK1 protects against mechanical overload-induced chondrocyte senescence by preserving mitochondrial function .
Kidney Disorders: Dysregulation contributes to phosphate homeostasis defects .
Methodological answer: Use in vitro overlay assays with NHE3 C-terminal fragments (aa 475–832) to map binding regions. For example:
Key findings:
Data conflict: NHERF2/NHERF3 heterodimerization is critical for carbachol inhibition , while NHERF1 homodimerization involves PDZ2/CT interactions .
Resolution strategy:
Approach:
Time-lapse FRET: Measure energy transfer between Cy3-NHE3 and Cy5-NHERF3 at 0.5-μm plasma membrane sections under basal vs. Ca²⁺-elevated conditions .
Key result: FRET efficiency drops by 50% within 15 min post-Ca²⁺ elevation .
Validation: Parallel assays with NHERF1/2 to rule out compensatory interactions .
Mechanistic insight:
Protein interaction mapping: Prioritize truncation mutants (e.g., F1-F4 NHE3 fragments ) over yeast two-hybrid for direct binding validation.
Dynamic studies: Combine FRET with Ca²⁺ chelators (BAPTA-AM) to isolate NHERF3-specific effects .
Recombinant system selection: Use PS120 fibroblasts for reduced endogenous NHERF interference vs. Caco-2 for polarized epithelial contexts .